Shots:
- Boltz has partnered with Takeda to deploy its biomolecular AI platform across Takeda’s research organization, providing discovery teams access to proprietary foundation models, incl. BoltzMol-1 & BoltzProt-1, to accelerate AI-driven drug discovery
- The platform is designed to support in-silico molecular design, enabling structure prediction, affinity estimation, and generative design to enhance AI-driven drug discovery
- As per the deal, Takeda scientists will access the Boltz platform through the Boltz Lab interface & API, enabling integration into existing workflows and AI agent–driven design using natural language, while Boltz will collaborate on target-specific model optimization & Takeda will retain ownership of generated compounds
Ref: PRnewswire | Image: Boltz & Takeda | Press Release
Related News: Takeda Presents P-III (FirstLight & RadiantLight) Trial Data on Oveporexton for Narcolepsy Type 1 (NT1) at SLEEP 2026
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
